ReviewWiener medizinische Wochenschrift (1946)2022

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.

Arkady Ovchinnikov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.